MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Earnings for MyMD Pharmaceuticals, Inc. (MYMD)
Earnings in 2023 (TTM): $-3,999,950
According to MyMD Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-3,999,950. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MyMD Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-3,999,950 | $-3,999,950 |
| 2022 | $-15,197,336 | $-15,111,909 |
| 2021 | $-29,889,045 | $-29,880,138 |
| 2020 | $-9,487,824 | $-10,679,683 |
| 2019 | $-3,381,295 | $-3,888,249 |
| 2018 | $-10,849,034 | $-10,849,034 |
| 2017 | $-5,805,326 | $-5,805,326 |
| 2016 | $-3,303,538 | $-3,303,538 |
| 2015 | $-9,581,257 | $-9,311,913 |
| 2014 | $-3,127,167 | $-3,127,167 |
| 2013 | $-1,526,773 | $-1,526,773 |
| 2012 | $-2,612,424 | $-2,449,051 |
| 2011 | $-3,882,168 | $-3,584,278 |
| 2010 | $-1,203,296 | $-919,883 |
| 2009 | $-4,628,017 | $-4,628,017 |
| 2008 | $-1,235,095 | $-535,159 |
| 2007 | $-2,365,071 | $-1,724,614 |
| 2006 | $-10,083,509 | $-9,594,647 |
| 2005 | $-4,507,186 | $-4,507,186 |